EZH2 blocker combined therapy for T-cell and NK-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug combination for people with certain types of lymphoma that have not responded to standard treatments. The drug, zeprumetostat, targets a protein called EZH2 to help stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of T-cell or NK-cell lymphoma that has come back or not responded to treatment
- You have at least one tumor that can be seen on a scan or measured
- Your overall health allows you to be up and taking care of yourself (ECOG score 0-2)
- You have not taken an EZH2-blocking drug before and had to stop due to side effects
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a new drug, Zeprumetostat, in people with a type of lymphoma called PTCL that has come back or not responded to prior treatment. The study looks at how well the drug works and if it is safe.
This trial tests a combination of targeted drugs, including an EZH2 inhibitor, for people with peripheral T-cell lymphoma that did not respond to initial chemotherapy. It is designed for patients whose tumor has been genetically tested to guide treatment.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new combination of three drugs (EZH2 inhibitor, glofitamab, and gemcitabine/oxaliplatin) for patients with diffuse large B-cell lymphoma that has stopped responding to or come back after prior treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a new drug, zeprumetostat, in people with T-cell large granular lymphocyte leukemia that has come back or not responded to treatment. It aims to see if the drug is safe and effective for this condition.
Hear when a new Mature T-cell and NK-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.